FANDOM


Risperidone
Risperidone
Synonyms R-64766
Brand names Ozidal, Resdone, Ridal, Rispa, Risperdal, Risperon, Rixadone
IUPAC name

IUPAC name
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
ChemSpider

4895

DrugBank

DB00734

PubChem

5073

PDB fields

N/A

Formula

C23H27FN4O2

InChI
InChI
1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
InChIKey
InChIKey
RAPZEAPATHNIPO-UHFFFAOYSA-N
SMILES
SMILES
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
(Jmol 3D structure)
Mol. mass

410.4845 g/mol

Risperidone is an atypical antipsychotic that is on the World Health Organization's List of Essential Medicines and is used to treat schizophrenia, aggression in autism or Alzheimer's disease and bipolar mania.[1][2]

According to a 2001 review the average monthly weight gain with risperidone is 0.96 kg, making it second least prone to cause weight gain of the 6 atypicals studied in this review, after ziprasidone.[3] It is the most prone of the atypical antipsychotics (SGAs) to causing prolactin elevation (even outpacing some first-generation agents like chlorpromazine and haloperidol), with the exception of its active metabolite, paliperidone; it is also one of the most prone of SGAs for causing movement disorder side effects; it is significantly (statistically at p=0.05) less prone to cause sedation than chlorpromazine, zotepine and clozapine, statistically it is no more prone than other SGAs to cause sedation (although according to the AMH[4] it is more sedating than aripiprazole, and equally sedating to amisulpride, asenapine, chlorpromazine, clozapine, olanzapine and quetiapine).[5]

It is available as oral (in tablets and liquid) and intramuscular injections (usually as a depot).

External linksEdit

Reference listEdit

  1. World Health Organization (October 2013). "WHO Model List of Essential Medicines 18th list" (PDF). who.int. Geneva, Switzerland: World Health Organization. Retrieved 5 September 2014. 
  2. Brayfield, A, ed. (13 December 2013). "Risperidone". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 5 September 2014. 
  3. Wetterling, T (January 2001). "Bodyweight gain with atypical antipsychotics. A comparative review.". Drug Safety 24 (1): 59–73. PMID 11219487. doi:10.2165/00002018-200124010-00005. 
  4. Rossi, S, ed. (July 2014). "Comparison of adverse effects of some antipsychotics". Australian Medicines Handbook. Adelaide, Australia: Australian Medicines Handbook Pty Ltd. 
  5. Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.". Lancet 382 (9896): 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3. 

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.